Skip to main content

MINI REVIEW article

Front. Pharmacol.
Sec. Inflammation Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1447403

The Therapeutic Potential of Gelsolin in Attenuating Cytokine Storm, ARDS, and ALI in Severe COVID-19

Provisionally accepted
Juan Zhi Juan Zhi Kaixuan Zhao Kaixuan Zhao Juhui Liu Juhui Liu Dong Yang Dong Yang *Jin Xu Jin Xu Deng Xiaoming Deng Xiaoming Haoyue Zhang Haoyue Zhang
  • Department of Anesthesiology, Plastic Surgery Hospital (PSH), Chinese Academy of Medical Sciences andPeking Union Medical College, Beijing, China

The final, formatted version of the article will be published soon.

    Severe COVID-19 cases often progress to life-threatening conditions such as acute respiratory distress syndrome (ARDS), sepsis, and multiple organ dysfunction syndrome (MODS). Gelsolin (GSN), an actin-binding protein with anti-inflammatory and immunomodulatory properties, is a promising therapeutic target for severe COVID-19. Plasma GSN levels are significantly decreased in critical illnesses, including COVID-19, correlating with dysregulated immune responses and poor outcomes. GSN supplementation may mitigate acute lung injury, ARDS, and sepsis, which share pathophysiological features with severe COVID-19, by scavenging actin, modulating cytokine production, enhancing macrophage phagocytosis, and stabilizing the alveolar-capillary barrier. Preliminary data indicate that recombinant human plasma GSN improves oxygenation and lung function in severe COVID-19 patients with ARDS. Although further research is needed to optimize GSN therapy, current evidence supports its potential to mitigate severe consequences of COVID-19 and improve patient outcomes. This review provides a comprehensive analysis of the biological characteristics, mechanisms, and therapeutic value of GSN in severe COVID-19.

    Keywords: Gelsolin, COVID-19, ARDS, Ali, Cytokine storm, Inflammation

    Received: 11 Jun 2024; Accepted: 01 Jul 2024.

    Copyright: © 2024 Zhi, Zhao, Liu, Yang, Xu, Xiaoming and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Dong Yang, Department of Anesthesiology, Plastic Surgery Hospital (PSH), Chinese Academy of Medical Sciences andPeking Union Medical College, Beijing, 100730, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.